Dupilumab therapy in atopic dermatitis is safe during COVID‐19 infection era: A systematic review and meta‐analysis of 1611 patients

El‐Qushayri, Amr Ehab; Mahmoud, Mariam Abdelmageed; Salman, Samar; Nardone, Beatrice

doi:10.1111/dth.15476

Cited by 14 publications

(10 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A survey revealed that the majority of the AD patients experienced AD flares with mild worsening of the disease during the COVID‐19 pandemic 197 . Dupilumab seems to be safe and crucial for a better outcome of COVID‐19 and should be continued in AD patients during the COVID‐19 pandemic 198 . During COVID‐19, AIT was initiated and continued by most physicians in patients without indications of SARS‐CoV‐2 infection 199 .…”

Section: Management Of Allergic Diseases During the Covid‐19 Pandemicmentioning

confidence: 99%

Recent developments in the immunopathology of COVID‐19

Zhang

Sun

Wang

et al. 2022

Allergy

View full text Add to dashboard Cite

There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy of the COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID-19.

show abstract

Section: Management Of Allergic Diseases During the Covid‐19 Pandemicmentioning

confidence: 99%

Recent developments in the immunopathology of COVID‐19

Zhang

Sun

Wang

et al. 2022

Allergy

View full text Add to dashboard Cite

show abstract

“…Further confirmation of the antiviral potential of photochemotherapy comes from the finding of photoinactivation potential in plasma with Amotosalen and 3 J/cm 2 of UVA light of six RNA-enveloped viruses, including SARS CoV [ 57 ]. Beyond the newly explored therapeutic potential, the promising role of phototherapy is also related to its choice as a viable therapeutic alternative to immunomodulating/immunosuppressive drugs used in AD and similar conditions whose use should be limited because of their ability to impact vaccine-induced immune responses [ 58 , 59 , 60 , 61 ] and for their suppressive action on intrinsic antiviral immunity [ 62 , 63 , 64 ] except for dupilumab, whose evidence of use in the pandemic era is reassuring [ 65 , 66 , 67 ].…”

Section: Atopic Dermatitis Treatmentmentioning

confidence: 99%

Oxidative Stress and Phototherapy in Atopic Dermatitis: Mechanisms, Role, and Future Perspectives

et al. 2022

View full text Add to dashboard Cite

Atopic dermatitis is a chronic inflammatory skin disease in which the overproduction of reactive oxygen species plays a pivotal role in the pathogenesis and persistence of inflammatory lesions. Phototherapy represents one of the most used therapeutic options, with benefits in the clinical picture. Studies have demonstrated the immunomodulatory effect of phototherapy and its role in reducing molecule hallmarks of oxidative stress. In this review, we report the data present in literature dealing with the main signaling molecular pathways involved in oxidative stress after phototherapy to target atopic dermatitis-affected cells. Since oxidative stress plays a pivotal role in the pathogenesis of atopic dermatitis and its flare-up, new research lines could be opened to study new drugs that act on this mechanism, perhaps in concert with phototherapy.

show abstract

“…A survey revealed that the majority of the AD patients experienced AD flares with mild worsening of the disease during the COVID-19 pandemic 168 . Dupilumab seems to be safe and crucial for a better outcome of COVID-19 and should be continued in AD patients during the COVID-19 pandemic 169 .…”

Section: Management Of Allergic Diseases During the Covid-19 Pandemicmentioning

confidence: 99%

Recent developments in the immunopathology of COVID-19

Gao

Zhang

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

There has been an important change in the clinical characteristics and immune profile of COVID-19 patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4 and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) has been identified as an important cause of death of children with COVID-19. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. Atopic diseases, such as allergic asthma and rhinitis, have been shown to be associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, EAACI developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging SARS-CoV-2 variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID.

show abstract

Dupilumab therapy in atopic dermatitis is safe during COVID‐19 infection era: A systematic review and meta‐analysis of 1611 patients

Cited by 14 publications

References 37 publications

Recent developments in the immunopathology of COVID‐19

Recent developments in the immunopathology of COVID‐19

Oxidative Stress and Phototherapy in Atopic Dermatitis: Mechanisms, Role, and Future Perspectives

Recent developments in the immunopathology of COVID-19

Contact Info

Product

Resources

About